Text to speech

Over 30 New Alzheimer’s Drugs in the Pipeline

By | July 21st, 2017

Twenty-seven Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials are expected to  launch in the next five years, according to a revised Alzheimer’s pipeline analysis presented by ResearchersAgainstAlzheimer’s (RA2), a network of top scientists in the field of Alzheimer’s research. That’s a significant increase in the number of trials since last year and scientists are hopeful that this new momentum will yield real results. There are currently 23 drugs in Phase II and III trials targeting amyloid protein buildup in the brain and 28 drugs targeting neurotransmitter activity. 

Deaths from dementia continue to rise, with the a recent report by the Centers for Disease Control and Prevention stating that Alzheimer’s deaths in the U.S. increased by 55 percent from 1999-2014. Despite this worrying trend, a new treatment for Alzheimer’s hasn’t been approved by the FDA since 2003 and the European Union since 2002.  These late-stage Alzheimer’s drugs provide much-needed hope to those with Alzheimer’s and their caregivers who are desperate for a treatment or cure. According to the analysis, six drugs will conclude Phase III trials in 2017. George Vradenburg, UsAgainstAlzheimer’s Co-Founder and Chairman, said he was ‘cautiously optimistic’ that there would be solutions for the disease in the near future.

Here’s where you can read more.

If you find our articles and interviews helpful, please consider becoming a supporting member of our community. Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient. We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.

Please help support our mission.

Leave a Reply

We are glad you have chosen to leave a comment. Please keep in mind that comments are moderated according to our comment policy.